Lv52
969 积分 2021-07-11 加入
RAS at 40: Update from the RAS Initiative
3小时前
已完结
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
1天前
已完结
Inavolisib: First Approval
1天前
已完结
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer
1天前
已完结
Curvature-Sensing Peptides for Virus and Extracellular Vesicle Applications
18天前
已完结
Membrane organization by tetraspanins and galectins shapes lymphocyte function
19天前
已完结
Possible Direction of Drug Discovery Based on Single-Molecule Live Imaging
1个月前
已完结
PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective
2个月前
已关闭
Combinatorial strategies to target RAS-driven cancers
2个月前
已完结
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
2个月前
已完结
皖公网安备34019202002308
